Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Neutral 62.8%

Neg 0% Neu 62.8% Pos 0%

Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.